Argos Therapeutics Inc. (NASDAQ:ARGS) major shareholder International S. Pharmstandard acquired 52,512 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The stock was acquired at an average price of $4.77 per share, with a total value of $250,482.24. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) opened at 4.78 on Wednesday. The stock’s 50 day moving average is $4.80 and its 200 day moving average is $5.96. The firm’s market cap is $196.92 million. Argos Therapeutics Inc. has a 12 month low of $1.61 and a 12 month high of $13.97.

Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. Equities research analysts expect that Argos Therapeutics Inc. will post ($1.55) EPS for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/argos-therapeutics-inc-args-major-shareholder-acquires-250482-24-in-stock.html

Hedge funds and other institutional investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. acquired a new position in shares of Argos Therapeutics during the second quarter valued at approximately $137,000. California State Teachers Retirement System acquired a new position in shares of Argos Therapeutics during the second quarter valued at approximately $137,000. KCG Holdings Inc. acquired a new position in shares of Argos Therapeutics during the second quarter valued at approximately $163,000. BlackRock Investment Management LLC raised its position in shares of Argos Therapeutics by 2,162.3% in the second quarter. BlackRock Investment Management LLC now owns 39,567 shares of the biopharmaceutical company’s stock valued at $243,000 after buying an additional 37,818 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 3,559 shares during the last quarter. 11.05% of the stock is owned by institutional investors.

ARGS has been the subject of several analyst reports. FBR & Co restated a “buy” rating on shares of Argos Therapeutics in a report on Tuesday, June 14th. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Argos Therapeutics in a report on Friday, June 17th. Piper Jaffray Cos. restated an “overweight” rating and set a $11.00 price target on shares of Argos Therapeutics in a report on Monday, June 20th. Finally, Zacks Investment Research lowered shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. Eight investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $11.50.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

5 Day Chart for NASDAQ:ARGS

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.